Yoshimi Aoyagi

509 total citations
20 papers, 440 citations indexed

About

Yoshimi Aoyagi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yoshimi Aoyagi has authored 20 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yoshimi Aoyagi's work include Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (5 papers) and HER2/EGFR in Cancer Research (4 papers). Yoshimi Aoyagi is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer therapeutics and mechanisms (5 papers) and HER2/EGFR in Cancer Research (4 papers). Yoshimi Aoyagi collaborates with scholars based in Japan, United States and Iran. Yoshimi Aoyagi's co-authors include Yuji Yamada, Tetsuji Asao, Konstanty Wierzba, Teruhiro Utsugi, Masaki Sano, Akihiro Hashimoto, Kazuhiko Yonekura, Yoshikazu Sugimoto, Kazutaka Miyadera and Takashi Kobunai and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Yoshimi Aoyagi

20 papers receiving 432 citations

Peers

Countries citing papers authored by Yoshimi Aoyagi

Since Specialization

Citations

This map shows the geographic impact of Yoshimi Aoyagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshimi Aoyagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshimi Aoyagi more than expected).

Fields of papers citing papers by Yoshimi Aoyagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshimi Aoyagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshimi Aoyagi. The network helps show where Yoshimi Aoyagi may publish in the future.

Co-authorship network of co-authors of Yoshimi Aoyagi

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshimi Aoyagi. A scholar is included among the top collaborators of Yoshimi Aoyagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshimi Aoyagi. Yoshimi Aoyagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MO13-2 Covalent FGFR inhibitor futibatinib exhibits sustained antitumor effects compared with ATP-competitive inhibitors 2023 ·Annals of Oncology ·Hiromi Muraoka, Hiroshi Sootome, Yoshimi Aoyagi, (unknown), (unknown), Hiroshi Hirai	1
2	TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X 2019 ·Molecular Cancer Therapeutics ·Kimihiro Ito, Makoto Nishio, Masanori Kato, Haruyasu Murakami, Yoshimi Aoyagi, Yuichiro Ohe, (unknown), Akihiro Hashimoto, Hirokazu Ohsawa, (unknown), Katsumasa Nonoshita, Satoru Ito, Kenichi Matsuo, Kazutaka Miyadera	10
3	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations 2018 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Naomi Abe, (unknown), Hirokazu Ohsawa, Akihiro Hashimoto, (unknown), Kenji F. Tanaka, (unknown), Renu Wadhwa, Kazutaka Miyadera, Yoshimi Aoyagi, Kazuhiko Yonekura, Kenichi Matsuo	70
4	401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling 2014 ·European Journal of Cancer ·Motoyasu Kato, Kazutaka Miyadera, Ken Ito, Yoshimi Aoyagi, Akihiro Hashimoto, Kazuya Yonekura, (unknown), Teruhiro Utsugi	2
5	The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile 2013 ·Molecular Cancer Therapeutics ·Hidenori Fujita, Kazutaka Miyadera, Masanori Kato, (unknown), (unknown), (unknown), Kimihiro Ito, Yoshimi Aoyagi, Toru Takenaka, Takamasa Suzuki, Satoko Ito, Akihiro Hashimoto, (unknown), (unknown), Hideki Kazuno, (unknown), Kazuto Nishio, Kazuhiko Yonekura	30
6	Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity. 2013 ·Molecular Cancer Therapeutics ·Masanori Kato, Kazutaka Miyadera, Yoshihiro Shibata, Kimihiro Ito, Yoshimi Aoyagi, Masato Chiba, Kazuhiko Yonekura, Yoshikazu Iwasawa, Teruhiro Utsugi	1
7	Abstract C111: In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI. 2013 ·Molecular Cancer Therapeutics ·Kimihiro Ito, Kazutaka Miyadera, Yoshimi Aoyagi, Masanori Kato, Kazuhiko Yonekura, Yoshikazu Iwasawa, Teruhiro Utsugi	2
8	142 TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models 2012 ·European Journal of Cancer ·Kazutaka Miyadera, Masanori Kato, (unknown), Ken‐ichi Ito, Yoshimi Aoyagi, Kazuya Fukasawa, (unknown), Kazuya Yonekura, (unknown), Teruhiro Utsugi	3
9	Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs 2012 ·Cancer Research ·Hidenori Fujita, Masanori Kato, (unknown), (unknown), (unknown), (unknown), Kimihiro Ito, Yoshimi Aoyagi, Takamasa Suzuki, Satoko Ito, Kenjiro Ito, Akihiro Hashimoto, (unknown), Kazutaka Miyadera, Kazuhiko Yonekura	1
10	Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile 2011 ·Cancer Research ·Hidenori Fujita, Kazutaka Miyadera, Kimihiro Ito, Toru Takenaka, (unknown), Satoko Ito, Takamasa Suzuki, (unknown), (unknown), (unknown), Ayako Sato, (unknown), (unknown), Masanori Kato, Yoshimi Aoyagi, Akihiro Hashimoto, Hideki Kazuno, (unknown), Kazuhiko Yonekura	1
11	Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis 2011 ·Cancer Research ·(unknown), Hidenori Fujita, Kimihiro Ito, Toru Takenaka, (unknown), Satoko Ito, Takamasa Suzuki, (unknown), (unknown), Ayako Sato, (unknown), (unknown), Masanori Kato, Yoshimi Aoyagi, Akihiro Hashimoto, Hideki Kazuno, Kazutaka Miyadera, (unknown), Kazuhiko Yonekura	2
12	TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. 2005 ·PubMed ·Yasuji Yamamoto, Jiro Shibata, Kazuhiko Yonekura, (unknown), Akihiro Hashimoto, Yoshimi Aoyagi, Konstanty Wierzba, Shingo Yano, Tetsuji Asao, Aman U. Buzdar, (unknown)	29
13	A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity 2005 ·Cancer Science ·Yoshimi Aoyagi, Norio Masuko, Shuichi Ohkubo, (unknown), Kentaro Nagai, (unknown), Konstanty Wierzba, (unknown), Yoshikazu Sugimoto, Yuji Yamada	18
14	TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect 2005 ·Clinical Cancer Research ·Yasuji Yamamoto, Jiro Shibata, Kazuhiko Yonekura, (unknown), Akihiro Hashimoto, Yoshimi Aoyagi, Konstanty Wierzba, Shingo Yano, Tetsuji Asao, Aman U. Buzdar, (unknown)	28
15	Synthesis of the novel analogues of dysidiolide and their structure–activity relationship 2000 ·Bioorganic & Medicinal Chemistry Letters ·Masato Takahashi, Kosuke Dodo, Yoshikazu Sugimoto, Yoshimi Aoyagi, Yuji Yamada, Yuichi Hashimoto, Ryuichi Shirai	56
16	Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines 2000 ·PubMed Central ·Yoshimi Aoyagi, Takashi Kobunai, Teruhiro Utsugi, Konstanty Wierzba, (unknown)	5
17	New Cdc25B Tyrrosine Phosphatase Inhibitors, Nocardiones A and B, Produced by Nocardia sp. TP-A0248. Taxonomy, Fermentation, Isolation, Structural Elucidation and Biological Prbperties. 2000 ·The Journal of Antibiotics ·TOSHIO OTANI, Yoshikazu Sugimoto, Yoshimi Aoyagi, (unknown), TAMOTSU FURUMAI, (unknown), Yuji Yamada, Tetsuji Asao, (unknown)	37
18	Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity. 2000 ·PubMed ·Jiro Shibata, Koji Murakami, Konstanty Wierzba, Yoshimi Aoyagi, Akihiro Hashimoto, Masaki Sano, (unknown), Yuji Yamada	8
19	In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II 1999 ·Japanese Journal of Cancer Research ·Yoshimi Aoyagi, Takashi Kobunai, Teruhiro Utsugi, Tomoko Oh‐hara, Yuji Yamada	33
20	Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II 1997 ·Japanese Journal of Cancer Research ·Teruhiro Utsugi, (unknown), Tetsuji Asao, (unknown), Yoshimi Aoyagi, Masaki Sano, Konstanty Wierzba, Yuji Yamada	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact